Results 281 to 290 of about 1,703,096 (348)
Some of the next articles are maybe not open access.
Self-Assembled Double-Bundle DNA Tetrahedron for Efficient Antisense Delivery.
ACS Applied Materials and Interfaces, 2018DNA nanostructures are promising biomaterials capable of arranging multiple functional components with nanometer precision. Here, a double-bundle DNA tetrahedron is rationally designed to integrate with antisense oligonucleotides silencing proto-oncogene
Juanjuan Yang +9 more
semanticscholar +1 more source
The delivery of antisense therapeutics
Advanced Drug Delivery Reviews, 2000Antisense oligonucleotides, ribozymes and DNAzymes have emerged as novel, highly selective inhibitors or modulators of gene expression. Indeed, their use in the treatment of diseases arising from genetic abnormalities has become a real possibility over the past few years. The first antisense drug molecule is now available for clinical use in Europe and
S, Akhtar +7 more
openaire +2 more sources
Cellular delivery of antisense oligonucleotides
European Journal of Pharmaceutics and Biopharmaceutics, 2000Antisense oligonucleotides can be successfully employed to inhibit specifically gene expression. However, many oligonucleotide classes are polyanions and cannot passively transit the cell membrane. Thus, the use of naked oligonucleotides for antisense purposes poses some rather stringent challenges, and it is not a trivial task to appropriately ...
I, Lebedeva +3 more
openaire +2 more sources
Transdermal delivery of antisense compounds
Advanced Drug Delivery Reviews, 2000Antisense technology holds tremendous promise for therapeutic applications and the study of gene function. A broadly applicable route of administration that would provide for non-invasive, simple, and convenient delivery is highly desirable. Application of oligonucleotides to the skin may represent a solution to the delivery question for both local ...
R M, Brand, P L, Iversen
openaire +2 more sources
Dendrimer-Enabled Therapeutic Antisense Delivery Systems as Innovation in Medicine.
Bioconjugate chemistry, 2019Antisense oligonucleotide (AON)-based therapies concern the treatment for genetic disorders or infections such as a range of neurodegenerative and neuromuscular diseases and have shown benefits in animal models and patients.
S. Mignani +3 more
semanticscholar +1 more source
Transdermal Delivery of Antisense Oligonucleotides
2004In recent years, antisense oligodeoxynucleotides (ODNs) have emerged as promising biopharmaceutical therapeutics. These agents specifically target genes or gene transcripts involved in pathogenesis. Several clinical trials have demonstrated the therapeutic value and low toxicity of ODNs (1–5).
Rhonda M, Brand, Patrick L, Iversen
openaire +3 more sources
Antisense oligonucleotides: strategies for delivery
Pharmaceutical Science & Technology Today, 1998Abstract The development of antisense oligonucleotides as therapeutic agents has progressed significantly over the past 10–15 years. In order for antisense oligodeoxynucleotides to become effective therapeutic agents, improvement in the delivery and distribution of these compounds must occur.
Keith J Miller, Sudip K Das
openaire +1 more source
Oral Delivery of Antisense Oligonucleotides in Man
Journal of Pharmaceutical Sciences, 2008Treatment of systemic disease with phosphorothioate antisense oligonucleotides (PS ASOs) has been accomplished using local or parenteral routes of administration to date. This report describes, for the first time, the effective oral delivery of a second generation oligonucleotide where significant milligram amounts of intact drug are absorbed in human ...
Lloyd G, Tillman +2 more
openaire +2 more sources
Comparison of antisense oligonucleotide drug delivery systems
Journal of Controlled Release, 2004Antisense oligonucleotides (AS-ONs) are specific drugs to inhibit gene expression at the transcriptional level. They possess a poor bioavailability and can be degraded by nucleases very rapidly. Therefore, a strong need for the development of oligonucleotide drug delivery systems exists. In the present study, two commercially available liposomes (DOTAP,
Jörg, Weyermann +2 more
openaire +2 more sources
Delivery of antisense oligonucleotides to PC12 cells
Neuroscience Research, 2002Optimal experimental conditions for the delivery of phosphodiester or phosphorothioate antisense oligonucleotides (P-ASO/S-ASO) to PC12 cells were determined. Fluorescently labeled P-ASO or S-ASO were transfected to PC12 cells and the uptake of antisense, free or entrapped in liposomes, was monitored by confocal and fluorescent microscopy.
Rosalinda, Acosta +3 more
openaire +2 more sources